SCHEMBL3475758

SCHEMBL3475758

CN1CCC(CCCN(C)c2ccc(C=O)cn2)CC1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.36
ALDH1A1 P00352 4/20 0.35
NMT1 P30419 5/20 0.35
HRH3 Q9Y5N1 1/20 0.34
KDM4E B2RXH2 4/20 0.33
NPSR1 Q6W5P4 2/20 0.33
LMNA P02545 2/20 0.33
HPGD P15428 2/20 0.33
MCOLN3 Q8TDD5 1/20 0.33
NLRP3 Q96P20 1/20 0.33
HCAR3 P49019 1/20 0.33
MEN1 O00255 1/20 0.32
TSHR P16473 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD17B10 Q99714 1/20 0.32
NR3C1 P04150 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3476796 0.85 NMT1 (0.35) ACHEALDH1A1NMT1HRH3
SCHEMBL3475694 0.80 KDM1A (0.42) HRH3
SCHEMBL1625904 0.77 KDM4E (0.41) ACHEALDH1A1NMT1HRH3KDM4E
SCHEMBL1626212 0.72 HPGD (0.49) ACHEALDH1A1HRH3LMNAHPGD
SCHEMBL23171392 0.72 HCAR3 (0.58) ALDH1A1KDM4EHCAR3
SCHEMBL24605670 0.70 POLB (0.47) ALDH1A1KDM4EHCAR3
SCHEMBL3476481 0.70 HRH4 (0.52)
SCHEMBL3477164 0.69 HRH4 (0.55)
SCHEMBL13183858 0.69 HRH4 (0.35)
SCHEMBL20220947 0.69 ALDH1A1 (0.41) ACHEALDH1A1NMT1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004188-B1 BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2010-09-01 EP disclosed
US-7589087-B2 Benzoimidazol-2-yl pyridines as modulators of the histamine H4receptor JANSSEN PHARMACEUTICA, N.V. (BE) 2009-09-15 US disclosed
EP-2004188-A4 BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2009-04-22 EP disclosed
EP-2004188-A2 BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-12-24 EP disclosed
WO-2007117400-A2 BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-18 WO disclosed
US-20070232616-A1 Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232616-A1 Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor HRH4, HRH3, HRH2 ACHE 2183/4885ALDH1A1 3919/4885NMT1 2056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.